Arcturus’ COVID-19 Vaccine Phase 3 Study Shows Promising Results
San Diego, Calif.-based Arcturus Therapeutics said that its messenger RNA (mRNA) vaccine has demonstrated strong protection against COVID-19 in a large late-stage study.
The phase 3 trial in Vietnam enrolled more than 16,000 participants. Two doses of the company’s ARCT-154 COVID-19 vaccine showed 55 percent efficacy in preventing COVID-19 infection and 95 percent efficacy at preventing severe COVID-19 disease, the company said.
Arcturus said it is working with the FDA, the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency to get the vaccine approved.
April 22, 2022
